Business
RepliCel's Partnership Initiatives Mature into Licensing Negotiations
RepliCel's Partnership Initiatives Mature into Licensing Negotiations.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel's Partnership Initiatives Mature into Licensing Negotiations\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel's Partnership Initiatives Mature into Licensing Negotiations\nPR Newswire\nVANCOUVER, Sept. 13, 2017\n\n\n\nDue diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises\n\n\n\nVANCOUVER, Sept. 13, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (\"RepliCel\" or the \"Company\"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it anticipates maturing discussions will lead to one or more new partnership agreements in the near-term. The Company's strategic focus on partnering has resulted in it being currently engaged in multiple negotiations with potential strategic partners.  \n\n\"The release of our positive clinical data earlier this year and the recent unveiling of our next-generation dermal injector prototypes have aggressively bolstered partnership negotiations,\" says RepliCel President and CEO, R. Lee Buckler. \"We remain confident of our ability to execute one or more partnerships for the dermal injector on our way to it being CE-marked by mid-2018, and have also generated significant partnership interest in our biologic assets among strong regional players. We believe it is highly likely that one of these will culminate in a partnership transaction in the near-term.\"\n\nRepliCel's partnership strategy is driven by an intent to identify and negotiate transactions with partners prepared to be investors and co-development partners for defined regional markets that will eventually provide access to their established commercial distribution channels.  \n\nIn Asia, partnership discussions are focused on the Company's dermatology and tendinopathy programs, as well as the Company's next-generation dermal injector, which is expected to be European market-ready next year. The Company is working with a Canadian firm specializin...